Combined radiochemotherapy in patients with locally advanced pancreatic cancer: a meta-analysis
- PMID: 24259979
- PMCID: PMC3831230
- DOI: 10.3748/wjg.v19.i42.7461
Combined radiochemotherapy in patients with locally advanced pancreatic cancer: a meta-analysis
Abstract
Aim: To compare the long-term clinical efficacy of chemotherapy plus radiotherapy (CRT) with that of radiotherapy alone (RT) or chemotherapy alone (CT) for locally advanced pancreatic carcinoma (LAPC).
Methods: Using manual and computer-aided methods, we searched the data through the databases, including PubMed/EmBase/CNKI/CQVIP/China Journals Full Text Database and websites and proceedings of major annual meetings such as ASCO and CSCO. The methodological quality of the included studies was assessed using the Jadad scoring system. Both English and Chinese publications were searched. We collected data from controlled clinical trials on CRT vs RT or CT for LAPC, and conducted a meta-analysis of 15 included studies. Meta-analysis was performed using RevMan4.2 Software according to the method recommended by Cochrane Collaboration.
Results: Fifteen eligible randomized controlled trials including a total of 1128 patients were screened. Jadad score was 2 in only one article, and 3-4 in the remaining 14 studies. The meta-analysis showed that CRT was superior in the 6- and 12-mo survivals to the RT alone group or CT alone group (P = 0.0001 and P = 0.02, respectively), whereas the 18-mo survival showed no significant difference (P = 0.23). Subgroup analysis showed that the 6-, 12-, and 18-mo survivals were not significantly different between the CRT group and CT group (P = 0.07, P = 0.23, and P = 0.91, respectively). Notably, the CRT group had significantly better 6-, 12-, and 18-mo survivals than the RT group (all P < 0.01). CRT group had significantly more grade 3-4 treatment-related hematologic and non-hematologic toxicities than the CT group or RT group (all P < 0.01).
Conclusion: Compared with CT or RT, CRT can benefit the long-term survival of LAPC patients, although it may also increase treatment-related toxicities.
Keywords: Chemotherapy; Meta-analysis; Pancreatic cancer; Radiotherapy; Survival.
Figures


Similar articles
-
Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer.Cancer. 2017 Oct 1;123(19):3816-3824. doi: 10.1002/cncr.30780. Epub 2017 Jun 16. Cancer. 2017. PMID: 28621885
-
Addition of radiotherapy to adjuvant chemotherapy is associated with improved overall survival in resected pancreatic adenocarcinoma: An analysis of the National Cancer Data Base.Cancer. 2015 Dec 1;121(23):4141-9. doi: 10.1002/cncr.29652. Epub 2015 Aug 17. Cancer. 2015. PMID: 26280559
-
Chemotherapy with or Without Definitive Radiation Therapy in Inoperable Pancreatic Cancer.Ann Surg Oncol. 2018 Apr;25(4):1026-1033. doi: 10.1245/s10434-017-6322-4. Epub 2018 Jan 11. Ann Surg Oncol. 2018. PMID: 29327180 Free PMC article.
-
Adjuvant chemoradiotherapy vs. radiotherapy alone in early-stage high-risk endometrial cancer: a systematic review and meta-analysis.Eur Rev Med Pharmacol Sci. 2019 Jan;23(2):833-840. doi: 10.26355/eurrev_201901_16898. Eur Rev Med Pharmacol Sci. 2019. PMID: 30720192
-
Resection and radiochemotherapy of pancreatic cancer--the future?Langenbecks Arch Surg. 1998 Apr;383(2):134-44. doi: 10.1007/pl00008075. Langenbecks Arch Surg. 1998. PMID: 9641886 Review.
Cited by
-
A phase II trial of gemcitabine and erlotinib followed by ChemoProton therapy plus capecitabine and oxaliplatin for locally advanced pancreatic cancer.J Gastrointest Oncol. 2022 Aug;13(4):1989-1996. doi: 10.21037/jgo-22-327. J Gastrointest Oncol. 2022. PMID: 36092320 Free PMC article.
-
Large database utilization in health outcomes research in pancreatic cancer: an update.J Gastrointest Oncol. 2018 Dec;9(6):996-1004. doi: 10.21037/jgo.2018.05.15. J Gastrointest Oncol. 2018. PMID: 30603118 Free PMC article. Review.
-
The emerging role of stereotactic radiotherapy in gastrointestinal malignancies: a review of the literature and analysis from the Irish perspective.Ir J Med Sci. 2018 Nov;187(4):887-894. doi: 10.1007/s11845-018-1755-8. Epub 2018 Feb 8. Ir J Med Sci. 2018. PMID: 29423821 Review.
-
Small extracellular vesicle non-coding RNAs in pancreatic cancer: molecular mechanisms and clinical implications.J Hematol Oncol. 2021 Sep 8;14(1):141. doi: 10.1186/s13045-021-01149-4. J Hematol Oncol. 2021. PMID: 34496946 Free PMC article. Review.
-
Modeling Combined Chemotherapy and Particle Therapy for Locally Advanced Pancreatic Cancer.Front Oncol. 2015 Jul 6;5:145. doi: 10.3389/fonc.2015.00145. eCollection 2015. Front Oncol. 2015. PMID: 26217585 Free PMC article.
References
-
- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30. - PubMed
-
- Yip D, Karapetis C, Strickland A, Steer CB, Goldstein D. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev. 2006;(3):CD002093. - PubMed
-
- Hackert T, Büchler MW. Pancreatic cancer: advances in treatment, results and limitations. Dig Dis. 2013;31:51–56. - PubMed
-
- Niederhuber JE, Brennan MF, Menck HR. The National Cancer Data Base report on pancreatic cancer. Cancer. 1995;76:1671–1677. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials